A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

BACKGROUND: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Stryjewski, Martin E, Lentnek, Arnold, O’Riordan, William, Pullman, John, Tambyah, Paul Anantharajah, Miró, Jose M, Fowler Jr, Vance G, Barriere, Steven L, Kitt, Michael M, Corey, G Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048626/
https://www.ncbi.nlm.nih.gov/pubmed/24884578
http://dx.doi.org/10.1186/1471-2334-14-289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048626/
https://www.ncbi.nlm.nih.gov/pubmed/24884578
http://dx.doi.org/10.1186/1471-2334-14-289

Ejemplares similares